Production (Stage)
Acrivon Therapeutics, Inc.
ACRV
$1.17
$0.021.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -83.75M | -80.56M | -76.98M | -69.00M | -64.12M |
| Total Depreciation and Amortization | 1.09M | 1.01M | 852.00K | 734.00K | 635.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.13M | 11.44M | 10.96M | 10.94M | 10.36M |
| Change in Net Operating Assets | 2.41M | 2.44M | 4.49M | 4.17M | 4.76M |
| Cash from Operations | -68.12M | -65.67M | -60.68M | -53.16M | -48.37M |
| Capital Expenditure | -2.01M | -2.77M | -3.09M | -2.10M | -2.08M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -36.40M | -49.00M | -42.56M | -58.04M | 49.32M |
| Cash from Investing | -38.41M | -51.77M | -45.65M | -60.14M | 47.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 70.01M | 70.09M | 70.41M | 70.48M | 854.00K |
| Repurchase of Common Stock | -2.70M | -2.52M | -3.17M | -1.97M | -1.46M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 53.55M | 53.46M | 52.43M | 52.74M | -1.12M |
| Cash from Financing | 120.86M | 121.03M | 119.66M | 121.25M | -1.73M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.33M | 3.59M | 13.34M | 7.95M | -2.85M |